Nanomi joins consortium to address chronic kidney disease
Advertisement
Nanomi, provider of microsphere-based drug delivery technologies to the pharmaceutical industry, announced that it joined a consortium for the development of a therapy to prevent chronic kidney disease.
The consortium partners, four companies, two universities and two academic hospitals, will jointly develop a therapy where biodegradable polymer microspheres, loaded with anti-inflammatory and anti-fibrotic compounds, will be implanted in the kidney. The impanted microspheres will provide a local drug depot with a sustained drug release profile, maximizing the intended therapeutic effects and minimizing systemic side-effects. The therapy aims to restore the kidney function, thus reducing the need for transplantations.
The Dutch Top Institute BioMedical Materials (BMM) — a public-private partnership dedicated to research and development of novel biomedical materials and their therapeutic application — has decided to fund this "top quality innovative R&D project" with approximately 4.2 million Euro.
Other news from the department business & finance
